why choose us

First received: February 07, 2023

Clinical Trial: D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients

Study Status: Completed

Recruit Status: RECRUITING

Condition: Newly Diagnosed MGMT Unmethylated Glioblastoma

Study Type: INTERVENTIONAL


Official Title: Delivery of D2C7-IT and 2141-V11 Combination Immunotherapy in Residual Disease for Adult Patients With Newly Diagnosed MGMT Unmethylated Glioblastoma and Perilymphatic Subcutaneous Injections of 2141-

Brief Summary: The purpose of this research study is to determine the safety and efficacy of administering a single intracerebral (within the brain) dose of investigational compounds called D2C7-immunotoxin (IT) and 2141-V11 in residual disease (within tumor margins) after surgery, followed by later repeated injections of 2141-V11 in the subcutaneous area (under the skin) around the lymph nodes of the head and neck for adults newly diagnosed with a type of cancerous brain tumor called glioblastoma.The word…

Read more